Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts

Neoplasia

Volumn 11, Issue 12, 2009, Pages 1285-1291

  Koskimaki, Jacob E ^a   Karagiannis, Emmanouil D ^a   Rosca, Elena V ^a   Vesuna, Farhad ^b   Winnard Jr , Paul T ^b   Raman, Venu ^b   Bhujwalla, Zaver M ^b   Popel, Aleksander S ^a  

^a Johns Hopkins University   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; CHEMOKINOSTATIN 1; COLLAGEN TYPE 4; PENTASTATIN 1; PEPTIDE; PROPERDISTATIN; THROMBOSPONDIN 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; DENSITY; DRUG SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROVASCULATURE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; TUMOR XENOGRAFT;

EID: 72949109758     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.09620     Document Type: Article

References (31)

1. Folkman J (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med 285, 1182-1186.
2. Carmeliet P (2005). Angiogenesis in life, disease and medicine. Nature 438, 932-936.
3. Carmeliet P and Jain RK (2000). Angiogenesis in cancer and other diseases. Nature 407, 249-257.
4. Fernando NT, Koch M, Rothrock C, Gollogly LK, D'Amore PA, Ryeom S, and Yoon SS (2008). Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin Cancer Res 14, 1529-1539.
5. Uzzan B, Nicolas P, Cucherat M, and Perret GY (2004). Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 64, 2941-2955.
6. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, and Thun MJ (2008). Cancer statistics, 2008. CA Cancer J Clin 58, 71-96.
7. Banerjee S, Dowsett M, Ashworth A, and Martin LA (2007). Mechanisms of disease: angiogenesis and the management of breast cancer. Nat Clin Pract Oncol 4, 536-550.
8. Doyle DM and Miller KD (2008). Development of new targeted therapies for breast cancer. Breast Cancer 15, 49-56.
9. Hayes DF, Miller K, and Sledge G (2007). Angiogenesis as targeted breast cancer therapy. Breast 16 (Suppl 2), S17-S19.
10. Salter JT and Miller KD (2007). Antiangiogenic agents in breast cancer. Cancer Invest 25, 518-526.
11. Schneider BP and Miller KD (2005). Angiogenesis of breast cancer. J Clin Oncol 23, 1782-1790.
12. Schneider BP and Sledge GW Jr (2007). Drug insight: VEGF as a therapeutic target for breast cancer. Nat Clin Pract Oncol 4, 181-189.
13. Guidi AJ, Schnitt SJ, Fischer L, Tognazzi K, Harris JR, Dvorak HF, and Brown LF (1997). Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer 80, 1945-1953.
14. Kut C, Mac Gabhann F, and Popel AS (2007). Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer 97, 978-985.
15. Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, and Harris AL (1997). Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57, 963-969.
16. Sachdev JC and Jahanzeb M (2008). Evolution of bevacizumab-based therapy in the management of breast cancer. Clin Breast Cancer 8, 402-410.
17. Choueiri TK (2008). Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. Curr Opin Investig Drugs 9, 658-671.
18. Jain RK (2008). Lessons from multidisciplinary translational trials on antiangiogenic therapy of cancer. Nat Rev Cancer 8, 309-316.
19. Clamp AR and Jayson GC (2005). The clinical potential of antiangiogenic fragments of extracellular matrix proteins. Br J Cancer 93, 967-972.
20. Folkman J (2007). Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6, 273-286.
21. Nakamura T and Matsumoto K (2005). Angiogenesis inhibitors: from laboratory to clinical application. Biochem Biophys Res Commun 333, 289-291.
22. Nyberg P, Xie L, and Kalluri R (2005). Endogenous inhibitors of angiogenesis. Cancer Res 65, 3967-3979.
23. Volpert OV (2000). Modulation of endothelial cell survival by an inhibitor of angiogenesis thrombospondin-1: a dynamic balance. CancerMetastasis Rev 19, 87-92.
24. Karagiannis ED and Popel AS (2008). A systematic methodology for proteomewide identification of peptides inhibiting the proliferation and migration of endothelial cells. Proc Natl Acad Sci USA 105, 13775-13780.
25. 6 fibrils of type IV collagen with anti-angiogenic properties. Biochem Biophys Res Commun 354, 434-439.
26. Karagiannis ED and Popel AS (2008). Novel anti-angiogenic peptides derived from ELR-containing CXC chemokines. J Cell Biochem 104, 1356-1363.
27. Karagiannis ED and Popel AS (2007). Anti-angiogenic peptides identified in thrombospondin type I domains. Biochem Biophys Res Commun 359, 63-69.
28. Meeker AK, Gage WR, Hicks JL, Simon I, Coffman JR, Platz EA, March GE, and De Marzo AM (2002). Telomere length assessment in human archival tissues: combined telomere fluorescence in situ hybridization and immunostaining. Am J Pathol 160, 1259-1268.
29. Ruegg C, Hasmim M, Lejeune FJ, and Alghisi GC (2006). Antiangiogenic peptides and proteins: from experimental tools to clinical drugs. Biochim Biophys Acta 1765, 155-177.
30. Vandercappellen J, Van Damme J, and Struyf S (2008). The role of CXC chemokines and their receptors in cancer. Cancer Lett 267, 226-244.
31. Bergers G and Hanahan D (2008). Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8, 592-603.